Daniel W Kung

This inventor holds 7 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Pfizer Corporation, Harvard College. Active years: 2004-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel W Kung. Retrieved from https://idiyas.com/inventor/daniel-w-kung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 42.9

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 15(Granted Patents)

Company Filing History:

Years Active: 2004-2016

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9296745 - Diacylglycerol acyltransferase 2 inhibitors (2016-03-29),

2. 8889730 - Indole and indazole compounds that activate AMPK (2014-11-18),

3. 8609680 - 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives (2013-12-17),

4. 7671072 - Aminopyrazole derivatives as GSK-3 inhibitors (2010-03-02),

5. 7300944 - Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors (2007-11-27),

6. 7202245 - Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines (2007-04-10),

7. 6809099 - Saframycins, analogues and uses thereof (2004-10-26),

Title: The Innovative Contributions of Daniel W Kung

Introduction

Daniel W Kung is a notable inventor based in Salem, CT (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 7 patents. His work primarily focuses on developing compounds that have therapeutic applications in various diseases.

Latest Patents

Among his latest patents, Kung has developed diacylglycerol acyltransferase 2 inhibitors. These include derivatives of purine, 3H-imidazo[4,5-b]pyrimidine, and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of diacylglycerol acyltransferase 2 (DGAT2). The applications of these compounds are aimed at treating diseases linked to DGAT2 activity in animals. Additionally, he has worked on indole and indazole compounds that activate 5' adenosine monophosphate-activated protein kinase (AMPK). This invention encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders that can be ameliorated by AMPK activation.

Career Highlights

Daniel W Kung has had a distinguished career, working with prominent organizations such as Pfizer Corporation and Harvard College. His experience in these institutions has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Throughout his career, Kung has collaborated with esteemed colleagues, including John William Benbow and Samit Kumar Bhattacharya. These partnerships have further enhanced his innovative work and expanded the impact of his inventions.

Conclusion

Daniel W Kung's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of therapeutic compounds that address critical health issues.

Profile summary based on public USPTO records.